Oslo, 26 March 2026: Reference is made to the stock exchange announcements by
EXACT Therapeutics AS ("EXACT-Tx" or the "Company") published on 27 February
2026 and 13 March 2026 regarding exercise of warrants and the extraordinary
general meeting to issue the new shares pursuant to the warrants exercise.
The issuance of the shares has now been registered with the Norwegian Register
of Business Enterprises (Nw: Foretaksregisteret). Following registration of the
share capital increase, the Company's share capital is NOK 446,176.244, divided
into 111,544,061 shares, each with a nominal value of NOK 0.004.
This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.
For more information, please contact:
Per Walday, CEO
Email per.walday@exact-tx.com
John M. Edminson, CFO
Email: john.edminson@exact-tx.com
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are traded on Euronext Growth Oslo (EXTX). Further
information may be found here: www.exact-tx.com